Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 20;41(9):1646-1648.
doi: 10.1200/JCO.22.02345. Epub 2023 Jan 12.

CAR T-Cells for Cure in Pediatric B-ALL

Rebecca A Gardner  1 , Nirali N Shah  2
Affiliations
Editorial

CAR T-Cells for Cure in Pediatric B-ALL

Rebecca A Gardner et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Nirali N. Shah

Research Funding: Lentigen (Inst)

Patents, Royalties, Other Intellectual Property: Receive royalties from Syncopation

No other potential conflicts of interest were reported.

Comment on

References

    1. Islami F, Ward EM, Sung H, et al. : Annual report to the nation on the status of cancer, part 1: National cancer statistics. J Natl Cancer Inst 113:1648-1669, 2021 - PMC - PubMed
    1. Laetsch TW, Maude SL, Rives S, et al. : Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol 41:1664-1669, 2023 - PMC - PubMed
    1. Wang T, Tang Y, Cai J, et al. : Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: A single-arm, multicenter, phase II trial. J Clin Oncol 41:1670-1683, 2023 - PMC - PubMed
    1. Maude SL, Laetsch TW, Buechner J, et al. : Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439-448, 2018 - PMC - PubMed
    1. Fry TJ, Shah NN, Orentas RJ, et al. : CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24:20-28, 2018 - PMC - PubMed